• Explosion in Idaho parking lot leaves one dead
  • How the Trump administration is reacting to Syria…
  • ‘We will retaliate’: Trump blames ISIS for attack…
  • 'We will retaliate’: Trump responds to deaths of…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

King Charles says his cancer treatment to be 'reduced'

admin - Latest News - December 12, 2025
admin
5 views 6 secs 0 Comments



King Charles says his cancer treatment to be ‘reduced’



Source link

TAGS:
PREVIOUS
Dec. 12, 2025, 4:16 PM ESTBy Rebecca KeeganLONG BEACH, Calif. — Commuters who were snaking along the 405 freeway in Southern California on Wednesday morning caught an unusual sight. Just about 800 feet above them, a 135-foot orange blimp drifted along the coast. Inside a gondola below the airship, the pilot was gently pumping foot pedals to steer the blimp over the Queen Mary and the L.A. River as the sun rose over the Pacific. The aim of this peaceful morning ride was in fact a bold one: to save independent film, or at least one film. Indie studio A24 rented the blimp to promote “Marty Supreme,” its new Timothée Chalamet movie that rolls out in theaters on Christmas Day. The blimp, which floated from Nashville to Los Angeles last month, is just the latest in a series of unusual marketing techniques the studio is deploying to spread the word about the film, which is about an aspiring ping-pong champion in post-World War II New York.“Marty Supreme” represents A24’s biggest production budget to date, at about $60 million. The marketing is an additional cost, which A24 has not disclosed, though it is widely believed to be less expensive than a traditional campaign because of its reliance more on unconventional stunts than on costly TV and outdoor ads.“It’s both more expensive and less effective to market a movie today than ever before,” said Daniel Loria, senior vice president of the Boxoffice Company, a theatrical e-commerce and data services firm. “Peoples’ attention spans are really divided.”A24 has dropped limited-edition merchandise, like a highly coveted $250 windbreaker, put their star on the cover of a Wheaties box and orchestrated a surprise premiere at the New York Film Festival. With an Instagram post from Chalamet, they alerted fans to a “Marty Supreme” streetwear popup in East Hollywood, generating crowds so big the LAPD was called. Chalamet and the film’s director, Josh Safdie, traveled to a fan event in Sao Paulo, Brazil, where they danced to Soulja Boy’s “Crank That” and handed out orange ping-pong balls. The movie’s maximum effort promotional campaign has even poked fun at itself, in an 18-minute mock Zoom meeting between Chalamet and a marketing team in which he proposed painting the Statue of Liberty orange. The strategy has been both weirder and more original than simply dropping a movie trailer and buying TV ads and billboards, a technique that used to be known as “spray and pray.” That’s because it takes creativity to get people to go see an offbeat movie in a theater in 2025, even when it stars Hollywood’s hottest young actor. During the pandemic, audiences learned to stay home and stream instead of heading to theaters, and domestic box office last year was still 24% below pre-pandemic levels. Enticing ticket buyers for movies that are not part of a well-known franchise is especially hard, and even stars don’t guarantee a big turnout. Despite Dwayne Johnson in the lead, A24’s “The Smashing Machine” opened to a disappointing $6 million in October, and Sydney Sweeney’s “Christie,” from Black Bear Pictures, also underperformed, earning just $1.3 million in a wide opening release.“What used to work doesn’t work now. It’s such a fractured, competitive environment,” said a veteran marketing executive, who spoke off the record because she was not authorized to comment on competitors. “People don’t think they need to go to the movie theaters anymore. The question becomes, ‘Is this theater worthy for me?’”Other studios have also been experimenting with unorthodox promotions this year. To help them open “Final Destination: Bloodlines” this spring, Warner Bros. sent logging trucks spattered with fake blood out onto highways, in a reference to one of the horror franchise’s infamous kill scenes. For an influencer screening of their Stephen King adaptation “The Long Walk,” Lionsgate had the audience walk on treadmills for the duration of the movie. To get crowds to Yorgos Lanthimos’s “Bugonia” this fall, Focus Features held “bald screenings“ for hairless moviegoers, a nod to Emma Stone’s character in the film. (Focus Features is a division of NBCUniversal, the parent company of NBC News.)There is a long history of Hollywood and movie theater owners getting inventive to attract crowds. To generate buzz around the 1973 dystopia “Soylent Green,” some theater owners filled their concession slushy machines with green food coloring, a reference to the film’s title, a mysterious and ultimately cannibalistic food source on an environmentally devastated future Earth. Also in 1973, for “The Exorcist,” theater owners paid to have ambulances parked outside, to imply to would-be moviegoers that the film is just that scary. “The showmanship aspect has always been there,” Loria said. “What’s new is the virality.”“Marty Supreme” will open in 70mm in a handful of theaters in New York City and Los Angeles on Dec. 18, ahead of a nationwide release on thousands of screens on Christmas Day. “This is the type of movie that needs all the help it can get,” Loria said. “It’s coming a week after ‘Avatar: Fire and Ash.’ It doesn’t have IP to grow on. It needs conversation starters.”With Chalamet nominated for a Golden Globe, and a likely Academy Award front-runner, for “A Complete Unknown,” A24 will look to keep the conversation rolling into the New Year. The blimp, however, is on its way home to Nashville.Rebecca KeeganRebecca Keegan is the senior Hollywood reporter for NBC News Digital, where she covers the entertainment industry.
NEXT
Dec. 12, 2025, 6:33 PM ESTBy Julia AinsleyWASHINGTON — White House pressure to ramp up deportations has sparked rising tension and finger-pointing inside the Department of Homeland Security, with the agency’s secretary, Kristi Noem, and her top advisor blaming subordinates for not hitting arrest quotas and undermining their relationships inside the West Wing, according to two DHS officials with direct knowledge of the matter. Noem and her close advisor Corey Lewandowski have sought to deflect blame from themselves for any White House frustration with the pace and scope of deportations, pinning it instead on the leaders of the agencies in charge of immigration enforcement — acting ICE Director Todd Lyons and Customs and Border Protection Commissioner Rodney Scott, the DHS officials said.Underscoring the turmoil, Scott recently expressed concern to colleagues that Lewandowski is able to monitor his emails, the two officials and another DHS official said, sparking concern among other top staffers that their messages were being reviewed.“Everyone in leadership is so worried about what they say in email and text,” one of the top staffers said.As the agency that carries out President Donald Trump’s mass deportations policy — a core tenet of his agenda — DHS is often under intense scrutiny both inside and outside the White House. The rising tensions within DHS come as deportation numbers continue to lag behind the administration’s own goals with Trump nearing the one-year mark of his second term.White House spokeswoman Abigail Jackson praised Noem’s performance when asked about the finger-pointing.“Secretary Noem is doing a great job implementing the president’s agenda and making America safe again,” Jackson said. “President Trump’s entire immigration team is on the same page when it comes to implementing the president’s agenda and the results speak for themselves — the border is secure, and deportations continue to increase.”Neither the White House spokesperson nor DHS assistant secretary for public affairs, Tricia McLaughlin responded to requests for comment on the finger-pointing and rising tensions inside the agency.Spokespeople for CBP and ICE did not respond to requests for comment.Trump campaigned on a promise to launch the largest mass deportation operation in U.S. history. But the effort has fallen short of expectations thus far. ICE is arresting fewer than 1,000 people a day on average, based on ICE data recently released as a result of a lawsuit, far below the 3,000 daily goal set by White House deputy chief of staff Stephen Miller in May. (The administration does not release deportation data.) The pressure on Noem and Lewandowski has led to tense confrontations within the Homeland Security Department, the two DHS officials said. Lyons has privately pushed back on the notion that it was his fault there wasn’t more space to detain immigrants and has defended himself to colleagues, the officials said. At one point he threatened to quit, arguing that Lewandowski — not him — was responsible for any decisions related to detention facilities, the officials said.ICE is now moving forward with plans to own and operate its own detention space out of large warehouses, as previously reported by NBC News.The two DHS officials said Scott has been left out of conversations about Border Patrol operations in major U.S. cities as well as social gatherings that have included other top DHS leaders. DHS leaders also have told Scott he may soon be out of a job, the officials said, despite record low border numbers during his tenure.One change in the upper ranks of the department came earlier this week. Noem’s deputy, Troy Edgar was told that Trump plans to name him as U.S. ambassador to El Salvador, a position that would remove him from the No. 2 spot at DHS, according to a person familiar with the plans.Julia AinsleyI am NBC News’ Senior Homeland Security Correspondent.Laura Strickler contributed.
Related Post
November 20, 2025
Americans opt for train travel this holiday season
October 1, 2025
Oct. 1, 2025, 5:00 AM EDTBy Abigail Brooks and Zinhle EssamuahWESTWEGO, Louisiana — Robin Phillip’s fresh haircut is dyed her favorite color — green. But beneath the dye job is a scar that runs along the side of her head, the result of two craniotomies. For years, Phillip, 45, suffered from what she thought were migraines. It wasn’t until early 2018, when she had to leave her warehouse shift to drive to the hospital, that she learned her headaches were a symptom of something more serious. She said she nearly crashed on the drive to the emergency room, blinded by pain. “The nurse said, ‘OK, what’s your pain from 1 to 10?’ I said 11, 12,” said Phillip. “They put me in the chair, and I don’t remember nothing after that.”Phillip awoke later to shocking news: She had an intracranial meningioma — a tumor of the lining of the brain. She needed emergency surgery.After the procedure, Phillip lost vision in her left eye and had to re-learn how to walk. Unable to work, she lost her apartment and moved in with her mother until she could get back on her feet. Robin Phillip during a radiation session in 2024. A mask holds her head in place for the treatment.Courtesy Robin Phillip“I was feeling lost, because where would I have possibly gotten a tumor from? I had a regular life. I did regular things,” she said. “What could have possibly caused this to happen to me?”Today, Phillip believes her birth control is to blame. For nearly 30 years, stopping only when she had her two children, she used Depo-Provera — a progestin shot given three times a year. She’s one of more than 1,000 women suing Pfizer, which makes the drug, alleging the company knew more about the risks and failed to warn users. Pfizer has moved to have the suit dismissed, arguing the case is pre-empted by a Food and Drug Administration decision, and says it stands behind the safety and efficacy of Depo-Provera.According to the Centers for Disease Control and Prevention, 1 in 4 sexually active women in the United States have used Depo-Provera. Black women use it at nearly double the national rate. Meningiomas are usually not cancerous — meaning they don’t spread to other parts of the body — but they can be harmful depending on their size and where they grow. Phillip’s tumor was pressing on her optic nerve, causing vision problems.Recent researchIn recent years, several studies have shown a possible link between Depo-Provera use and an increased risk of developing meningioma. One of them, published earlier this month in JAMA Neurology, linked medroxyprogesterone acetate (MPA), the drug in Depo-Provera, with a twofold increase in risk for meningioma. The risk was greatest in women who used the contraceptive for more than four years or started after age 31.Another one, a 2024 study published in the The BMJ based on French data, found a fivefold increase in risk for meningioma for long-term Depo-Provera users. Doctors caution that the studies are observational, meaning they cannot prove the medication caused the tumors. Dr. David Raleigh, a radiation oncologist who specializes in brain tumors and who is the chair of meningioma research at the University of California San Francisco’s Department of Radiation Oncology, said that female sex hormones — progesterone in particular — are linked to meningioma. (Progestin, the hormone in Depo-Provera, is a synthetic version of progesterone.) Meningiomas are the only brain tumors that are more common in women than in men, he added.Still, Raleigh said this doesn’t necessarily mean that progesterone is causing a meningioma to form. “All the available data suggest that progesterone is fuel on the fire,” he said. “Progesterone didn’t necessarily start the fire, but the available data suggest that it’s like dumping gas on it.” He said that the recent studies linking Depo-Provera to meningioma give him pause.“Those of us in the business often recommend that patients with meningioma avoid hormone replacement therapy, use nonhormone based means of contraception, if possible, and to be cautious with pregnancy and fertility planning because of these very well documented associations,” he said. “These new studies only amplify those concerns and considerations.”The overall risk of developing meningioma remains small: About 39,000 meningiomas are diagnosed each year in the U.S.“Overall, meningioma is not common. This is not a type of tumor that we see very often,” said Dr. Colleen Denny, an OB-GYN at NYU Langone Health. “The likelihood of having a meningioma as a Depo user is incredibly low. It’s just that it’s incredibly, incredibly low for people who don’t use Depo.”The American College of Obstetricians and Gynecologists (ACOG) published a response to The BMJ study urging caution, saying that, “according to the study, five out of 10,000 women using medroxyprogesterone acetate may possibly develop meningioma compared to one out of 10,000 women not using the medication.”“The risk that they’re finding is incredibly small,” said Dr. Nisha Verma, senior adviser for reproductive health policy for advocacy at ACOG. “I think it is a consideration we can talk to patients about, among all of the considerations that patients go through.”“Uterine cancer is a lot more common than meningioma, and Depo reduces your risk of uterine cancer. So how do you balance that?” Denny said. “It’s complex, and it often depends on the individual patients.”Phillip says even that small risk would have been too much for her.“If I would have [known] from the get-go, I would have never took that shot,” she said. The lawsuitPhillip is now one of more than 1,000 women suing Pfizer, the maker of Depo-Provera, alleging that the company failed to warn them about the risk. “These women all have meningiomas. Many have surgery, some have radiation, and they’ve all had their lives greatly impacted,” said Ellen Relkin, a lawyer representing Phillip and some of the other plaintiffs. Phillip’s lawsuit points to several studies dating as far back as 1983 showing a link between progesterone and meningioma. The lawsuit says those studies created an “unassignable duty to investigate,” and that Pfizer should have studied the risks associated with Depo-Provera sooner. Phillip needed two surgeries to remove a meningioma. A scar from the operations runs down the side of her head.NBC News“Defendants willfully, wantonly, and intentionally conspired, and acted in concert, to ignore relevant safety concerns and to deliberately not study the long-term safety and efficacy of Depo-Provera, particularly in chronic long-term users of Depo-Provera,” the complaint says. Verma, of ACOG, said that hormonal birth control is well-studied before it hits the market.“Birth control methods that are commercially available have been studied extensively before becoming available to the public, and so we’ve studied every type of birth control. We’ve looked at safety measures,” she said. “We have guidelines that do intensive reviews of all of the data and help us support patients in what methods may be safer for them.”In a statement to NBC News, Pfizer said it stands behind the “safety and efficacy of Depo-Provera.” In a court filing earlier this month, the company asked a judge to dismiss the case, saying that it became aware of the risks of meningioma associated with Depo-Provera in 2023, and submitted an application to the Food and Drug Administration to add a warning to the drug’s label. The application also requested adding warnings to two pills containing much lower doses of MPA. The FDA denied that request, according to the filing.The FDA declined NBC News’ request for comment, but in its denial letter to Pfizer, which is included in company’s filing, it said: “The findings of the available observational studies alone do not support the addition of a warning on Meningioma risk to medroxyprogesterone acetate (MPA)-containing products.”A spokesperson for Pfizer told NBC News that because of the FDA’s denial, federal law pre-empts the company from changing the warning label on Depo-Provera.In an interview with NBC News, Phillips’ lawyer Relkin said Pfizer had enough information to study the possible risks associated with Depo-Provera on its own before 2023 and accused the company of making an “overbroad and half-baked” effort to warn patients by submitting an application to add a warning label to every medication containing MPA.“Depo-Provera is 150 milligrams. Three, four times a year, a very high dose,” Relkin said. “There are low-dose, 2.5 and 5 mg pills, where there’s no data showing that they cause a problem.”“The dose makes the poison,” she added. “By asking to change the label for all, they were inviting a rejection.”Pfizer denied that accusation in its court filing. “If FDA truly thought a meningioma warning was necessary for some products (and not others) … FDA could have ‘promptly’ communicated to Pfizer,” it wrote.Changes abroad Outside of the U.S., however, changes have been made to Pfizer’s label.The European Medicines Agency added meningioma as a “possible side effect” of drugs with high doses of medroxyprogesterone acetate in 2024, and Pfizer went on to communicate that risk to doctors in the European Union. Canada’s label for the drug, updated in 2024, includes meningioma in its “warnings and precautions” section, stating that “meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate.”In January, South Africa’s drug regulatory agency also recommended updating the drug label for MPA to include meningioma risk. Phillip’s lawsuit alleges that Pfizer knew of the potential risk years before those changes overseas were made, however, citing a 2006 Canadian drug label which lists meningioma as one of the “Post-Market Adverse Drug Reactions” — adverse events that are reported after a drug has already been approved. The 2006 label notes that “the nature of post-marketing surveillance makes it difficult to determine if a reported event was actually caused by DEPO-PROVERA.”“Just because something happened associated in time with something, it doesn’t mean that one thing caused the other,” said Dr. Janet Woodcock, a former FDA principal deputy commissioner. “It’s in a company’s best interest to put everything on there, because then if they’re sued, they’d say, ‘Well, it was in the fine print.’”Woodcock, who is not involved with the lawsuit, noted the FDA typically has the final word on drug labels.According to Pfizer’s court filings, the company resubmitted its application to the FDA in June 2025. Phillip, right, rings the bell on her last day of radiation treatment on March 25, 2024.Courtesy Robin Phillip“FDA has still not approved any meningioma warning, and Pfizer’s renewed request remains pending,” the filing said.Relkin said an earlier warning would have changed everything for Phillip and her other clients.After her surgery in 2018, Phillip continued to take Depo-Provera. Her doctors were unable to remove the entire tumor in 2018 and she needed a second surgery in 2022, followed by radiation treatment from 2022 to 2024.Even still, doctors weren’t able to remove the entire tumor because of how close it is to her optic nerve.Phillip says she continued taking Depo-Provera until she saw posts on social media in 2024 about the studies linking the drug to meningioma. Earlier this month, she had her first set of brain scans since going off the drug. She said her radiologist told her that the meningioma is shrinking. “My body is telling me, my head is telling me I don’t have that much pain like I used to have,” she said. Abigail BrooksAbigail Brooks is a producer for NBC News.Zinhle EssamuahZinhle Essamuah is a correspondent and anchor for NBC News.
October 22, 2025
Pete Hegseth cracks down on Pentagon staff speaking to Congress
December 4, 2025
Lawmakers Call for Video of 2nd Strike on Alleged Drug Boat
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved